TABLE 3.

Comparison of pre-ECMO factors between the old and new regimen group after early ECMO intervention.

Variable	Total (n = 55)	Old regimen group (n = 15)	New regimen group (n = 40)	P
Indication for ECMO
Cardiogenic shock n (%)	18 (32.7)	0 (0)	18 (45)	<0.01*
Arrhythmia (VT/VF/AVB) n (%)	28 (50.9)	9 (60)	19 (47.5)	0.41
ECPR n (%)	9 (16.4)	6 (40)	3 (7.5)	<0.01*
Pre-ECMO cardiac arrest n (%)	14 (25.5)	7 (46.7)	7 (17.5)	0.03*
Pre-ECMO hemodynamic state
MAP (mmhg)	45.2 ± 22.4	30.7 ± 27.4	50.6 ± 17.8	<0.01*
LVEF	0.24 ± 0.13	0.16 ± 0.14	0.27 ± 0.11	0.02*
Laboratory examination
CK (U/L)	2,800 ± 1510	4,453 ± 2,180	2,180 ± 725	0.06
CK-MB (U/L)	190 ± 164	320 ± 204	142 ± 115	<0.01*
hs-TnT (ng/l)	3,892 ± 2521	5,006 ± 2658	3,475 ± 2369	0.04*
NT-proBNP (pg/l)	17,911 ± 10,763	21,655 ± 10,153	16,507 ± 10,770	0.12
Lac (mmol/l)	8.2 ± 6.5	12.1 ± 7.1	6.7 ± 5.6	<0.01*
Cr (mmol/l)	123.5 ± 84.3	131.3 ± 127.3	120.6 ± 63.9	0.7

ECMO, extracorporeal membrane oxygenation; VT, ventricular tachycardia; VF, ventricular fibrillation; AVB, atrioventricular block; ECPR, extracorporeal cardiopulmonary resuscitation; MAP, mean arterial pressure; LVEF, left ventricular ejection fraction; CK, creatine kinase; CK-MB, creatine kinase muscle/brain; hs-TnT, human hypersensitive troponin; NT-proBNP, N-terminal pro-B type natriuretic peptide; Lac: lactic acid; Cr: creatinine; *P < 0.05.